Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509. [Epub ahead of print]

PMID:
30211813
2.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231, 4RTNI, TAUROS; PROSPERA Investigators.

Parkinsonism Relat Disord. 2018 Sep 4. pii: S1353-8020(18)30384-5. doi: 10.1016/j.parkreldis.2018.08.025. [Epub ahead of print]

PMID:
30201421
3.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2018 Sep 6. doi: 10.1007/s11136-018-1984-3. [Epub ahead of print]

PMID:
30191365
4.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2018 Sep 6. pii: theoncologist.2018-0299. doi: 10.1634/theoncologist.2018-0299. [Epub ahead of print]

PMID:
30190302
5.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Sep 3. doi: 10.2217/imt-2018-0085. [Epub ahead of print]

6.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000483. [Epub ahead of print]

PMID:
30169431
7.

Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.

Gao X, McDermott DF.

Expert Opin Biol Ther. 2018 Sep;18(9):947-957. doi: 10.1080/14712598.2018.1513485. Epub 2018 Aug 30.

PMID:
30124333
8.

Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Gao X, McDermott DF.

Cancer J. 2018 Jul/Aug;24(4):171-179. doi: 10.1097/PPO.0000000000000323.

PMID:
30119080
9.

Supporting the Quality of Measurement and Evaluation in Education.

Mason D, Wentling W, Englert N, George L, Hampe H, Hellier S, Kaufmann J, Locasto L, McDermott D.

J Nucl Med Technol. 2018 Aug 3. pii: jnmt.118.210385. doi: 10.2967/jnmt.118.210385. [Epub ahead of print]

PMID:
30076250
10.

Developing a Framework for a Program Theory-Based Approach to Evaluating Policy Processes and Outcomes: Health in All Policies in South Australia.

Lawless A, Baum F, Delany-Crowe T, MacDougall C, Williams C, McDermott D, Eyk HV.

Int J Health Policy Manag. 2017 Oct 22;7(6):510-521. doi: 10.15171/ijhpm.2017.121.

11.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.

PMID:
29867230
12.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

13.

A Batf3/Nlrp3/IL-18 Axis Promotes Natural Killer Cell IL-10 Production during Listeria monocytogenes Infection.

Clark SE, Schmidt RL, McDermott DS, Lenz LL.

Cell Rep. 2018 May 29;23(9):2582-2594. doi: 10.1016/j.celrep.2018.04.106.

14.

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Gao X, Jegede O, Gray C, Catalano PJ, Novak J, Kwiatkowski DJ, McKay RR, George DJ, Choueiri TK, McDermott DF, Signoretti S, Bhatt RS.

Clin Genitourin Cancer. 2018 Apr 25. pii: S1558-7673(18)30164-2. doi: 10.1016/j.clgc.2018.04.001. [Epub ahead of print]

PMID:
29754934
15.

Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

Gao JL, Yim E, Siwicki M, Yang A, Liu Q, Azani A, Owusu-Ansah A, McDermott DH, Murphy PM.

J Clin Invest. 2018 Aug 1;128(8):3312-3318. doi: 10.1172/JCI120375. Epub 2018 Jun 25.

16.

Understanding Australian policies on public health using social and political science theories: reflections from an Academy of the Social Sciences in Australia Workshop.

Baum F, Graycar A, Delany-Crowe T, de Leeuw E, Bacchi C, Popay J, Orchard L, Colebatch H, Friel S, MacDougall C, Harris E, Lawless A, McDermott D, Fisher M, Harris P, Phillips C, Fitzgerald J.

Health Promot Int. 2018 Apr 19. doi: 10.1093/heapro/day014. [Epub ahead of print]

PMID:
29684128
17.

The priming function of in-car audio instruction.

Keyes H, Whitmore A, Naneva S, McDermott D.

Q J Exp Psychol (Hove). 2018 May 1:1747021818773293. doi: 10.1177/1747021818773293. [Epub ahead of print]

PMID:
29649945
18.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

PMID:
29562145
19.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
20.

Polistes metricus queens exhibit personality variation and behavioral syndromes.

Wright CM, Hyland TD, Izzo AS, McDermott DR, Tibbetts EA, Pruitt JN.

Curr Zool. 2018 Feb;64(1):45-52. doi: 10.1093/cz/zox008. Epub 2017 Mar 8.

21.

Description, Normative Data, and Utility of the Hearing Aid Skills and Knowledge Test.

Saunders GH, Morse-Fortier C, McDermott DJ, Vachhani JJ, Grush LD, Griest S, Lewis MS.

J Am Acad Audiol. 2018 Mar;29(3):233-242. doi: 10.3766/jaaa.16153.

PMID:
29488873
22.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

PMID:
29442540
23.

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK.

Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10.

PMID:
29439857
24.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
25.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.

PMID:
29358500
26.

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 3. No abstract available.

PMID:
29306512
27.
28.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

29.

"I Want to Feel Like a Full Man": Conceptualizing Gay, Bisexual, and Heterosexual Men's Sexual Difficulties.

McDonagh LK, Nielsen EJ, McDermott DT, Davies N, Morrison TG.

J Sex Res. 2018 Jul-Aug;55(6):783-801. doi: 10.1080/00224499.2017.1410519. Epub 2017 Dec 20.

PMID:
29261328
30.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

31.

Neuroimaging in Dementia.

Staffaroni AM, Elahi FM, McDermott D, Marton K, Karageorgiou E, Sacco S, Paoletti M, Caverzasi E, Hess CP, Rosen HJ, Geschwind MD.

Semin Neurol. 2017 Oct;37(5):510-537. doi: 10.1055/s-0037-1608808. Epub 2017 Dec 5. No abstract available.

32.

Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.

Liu Q, Li Z, Y Yang A, Gao JL, S Velez D, J Cho E, McDermott DH, Murphy PM.

J Clin Immunol. 2018 Jan;38(1):77-87. doi: 10.1007/s10875-017-0457-8. Epub 2017 Nov 24.

PMID:
29177911
33.

Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.

Heusinkveld LE, Yim E, Yang A, Azani AB, Liu Q, Gao JL, McDermott DH, Murphy PM.

Expert Opin Orphan Drugs. 2017;5(10):813-825. doi: 10.1080/21678707.2017.1375403. Epub 2017 Sep 25.

PMID:
29057173
34.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA.

J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.

35.

Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.

Einstein DJ, McDermott DF.

Clin Adv Hematol Oncol. 2017 Jun;15(6):478-488. Review.

PMID:
28749908
36.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, Choueiri TK.

Eur Urol Focus. 2016 Dec 15;2(6):633-639. doi: 10.1016/j.euf.2016.03.017. Epub 2016 Apr 23.

37.

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, McDermott DF, Atkins MB.

Cancer Med. 2017 Aug;6(8):1904-1914. doi: 10.1002/cam4.1140. Epub 2017 Jul 18.

38.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
39.

Embedding cultural safety in Australia's main health care standards.

Laverty M, McDermott DR, Calma T.

Med J Aust. 2017 Jul 3;207(1):15-16. No abstract available.

PMID:
28659104
40.

Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.

Einstein DJ, DeSanto-Madeya S, Gregas M, Lynch J, McDermott DF, Buss MK.

J Oncol Pract. 2017 Sep;13(9):e729-e737. doi: 10.1200/JOP.2016.020396. Epub 2017 May 31.

PMID:
28562197
41.

Dynamic phases, clustering, and chain formation for driven disk systems in the presence of quenched disorder.

Yang Y, McDermott D, Reichhardt CJO, Reichhardt C.

Phys Rev E. 2017 Apr;95(4-1):042902. doi: 10.1103/PhysRevE.95.042902. Epub 2017 Apr 10.

PMID:
28505834
42.

Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.

Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M, Dranoff G, Rodig S, Shipp M, Hodi FS.

Cancer Immunol Res. 2017 Jun;5(6):446-454. doi: 10.1158/2326-6066.CIR-16-0385. Epub 2017 May 4.

43.

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S.

Eur Urol. 2017 Sep;72(3):368-376. doi: 10.1016/j.eururo.2017.03.037. Epub 2017 Apr 12.

PMID:
28410865
44.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3. Erratum in: Eur Urol. 2018 Jan 3;:.

PMID:
28262413
45.

Developing a model for embedded palliative care in a cancer clinic.

DeSanto-Madeya S, McDermott D, Zerillo JA, Weinstein N, Buss MK.

BMJ Support Palliat Care. 2017 Sep;7(3):247-250. doi: 10.1136/bmjspcare-2016-001304. Epub 2017 Mar 3.

PMID:
28258162
46.
47.

Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.

Izar B, Regan MM, McDermott DF.

Cancer J. 2017 Jan/Feb;23(1):63-67. doi: 10.1097/PPO.0000000000000243. Review.

PMID:
28114257
48.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS.

Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.

49.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

50.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

Supplemental Content

Loading ...
Support Center